SCNI News and Press, Scanner Technologies Corp From 12/11/23

Study published in Antiviral Research supports promise of Scinai Immunotherapeutics' coronavirus NanoAb as aerosolized prophylactic and therapeutic drug PR Newswire Data backs use of Scinai's aerosolized NanoAbs as a platform for the treatment of hyperinflammatory viral diseases...

Many infectious disease specialist fellowship programs across the country remain unfulfilled with only 74% of ID fellowship positions and 56% of ID fellowship programs being filled on Match Day. The Infectious Diseases Society of America (IDSA) notes that the overall number of infectious diseas...

Scinai Immunotherapeutics (NASDAQ: SCNI) today announced the execution of a formal amendment to its finance contract with the European Investment Bank (“EIB”). According to the announcement, the amendment extends the maturity date of the contract by four years from Dec. 31, 2027, t...

European Investment Bank (EIB) extends maturity of its finance facility with Scinai Immunotherapeutics from 2027 to 2031 PR Newswire Significant positive impact to Scinai's financial health is expected Amendment made in light of Scinai's recent strategic shif...

Autoimmune diseases occur when the immune system becomes dysfunctional and begins attacking healthy tissue and organs. More than 20 million Americans suffer from a myriad of autoimmune diseases, such as thyroid disease, rheumatoid arthritis and lupus, that can significantly impact their quality...

Scinai Immunotherapeutics (NASDAQ: SCNI) , a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases, and providin...

2023-11-20 07:37:38 ET More on Scinai Immunotherapeutics Seeking Alpha’s Quant Rating on Scinai Immunotherapeutics Historical earnings data for Scinai Immunotherapeutics Financial information for Scinai Immunotherapeutics For further details see: S...

Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity Rule PR Newswire JERUSALEM , Nov. 20, 2023 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI ) today announced today the receipt of formal notification from the Nasdaq ...

Researchers believe worsening climate change could lead to the emergence of new and deadly infectious diseases. Climate change has the potential to significantly alter weather patterns globally and is already contributing to extreme weather events in several regions. A recent study from t...

Scinai Immunotherapeutics (NASDAQ: SCNI) , a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases, has been nam...